Estimated longevity benefit: +1.5 years. Evidence score: 100/100.
Shingrix (recombinant zoster vaccine) protects against herpes zoster reactivation and, in a 3,884-person cohort study, was associated with significantly slower biological aging across five independent measures — epigenetic age, pace of aging (DunedinPACE), transcriptomic age, proteomic age, and a composite biological age score — with effects persisting more than four years. The mechanism links latent herpesvirus suppression to reduced chronic inflammaging.
The primary evidence base for Shingrix as a longevity intervention comes from Kim & Crimmins (2025), a cohort analysis of the US Health and Retirement Study covering 3,884 adults aged 70 and over. Vaccinated individuals showed significantly slower biological aging across all five aging measures assessed: epigenetic age (p=0.0001), DunedinPACE epigenetic pace of aging (p=0.009), transcriptomic age (p=0.04), proteomic age (p=0.02), and a composite biological age score (p=0.009). Effects persisted for more than four years post-vaccination, suggesting this is not a transient immune stimulation artifact.
The mechanistic hypothesis centers on latent viral burden and inflammaging. Varicella-zoster virus (VZV) establishes permanent latency in dorsal root ganglia after primary chickenpox infection. As the immune system ages (immunosenescence), VZV reactivation — symptomatic as shingles or subclinical — generates chronic bursts of viral antigen that trigger ongoing immune responses. Each reactivation cycle contributes to the systemic low-grade inflammation that characterizes biological aging. Shingrix, by generating robust VZV-specific immunity (97.2% efficacy in adults 50–69 in the ZOE-50 RCT), suppresses this reactivation cycle and removes a driver of background inflammaging.
The VZV data have implications beyond this single vaccine. CMV and EBV — two other herpesviruses with near-universal adult seroprevalence — drive similar immune aging through the same latency-reactivation-inflammaging mechanism. The shingles vaccine provides proof of concept that vaccinating against latent viruses can slow biological aging at the population level, a framework that may extend to future CMV and EBV vaccine programs.
Limitations: The Kim & Crimmins study is observational (cohort), not a randomized controlled trial, and cannot fully exclude residual confounding (healthier individuals may be more likely to receive vaccination). However, the consistency across five independent aging biomarkers, the dose-response pattern, and the biological plausibility of the mechanism substantially strengthen the causal inference. The vaccine's efficacy against clinical shingles — the disease for which it was designed — is established by multiple phase 3 RCTs with over 30,000 participants.
What Shingrix Is: Shingrix (recombinant zoster vaccine, RZV) is a two-dose adjuvanted subunit vaccine made by GSK. It replaced the older live-attenuated Zostavax vaccine and is dramatically more effective: 97.2% efficacy against shingles in adults 50–69 (ZOE-50 trial) versus ~51% for Zostavax. Shingrix contains a recombinant VZV glycoprotein E antigen paired with the AS01B adjuvant system, which is responsible for the powerful immune response — and most of the expected side effects.
Who Should Get It: - All adults 50 and older in the United States (CDC recommendation), regardless of prior shingles history or prior Zostavax vaccination - Immunocompromised adults 18 and older (discuss timing with your physician — Shingrix is non-live and safe in immunocompromised individuals, though the response may be lower) - Adults who received Zostavax more than 2 years ago should still get Shingrix — Zostavax immunity wanes significantly with age
Dosing Schedule: - Two doses required for full protection - Second dose given 2 to 6 months after the first - Immunocompromised adults: second dose can be given 1 to 2 months after the first - Do not skip the second dose — a single dose provides substantially less durable protection
Where to Get It: - Major pharmacy chains (CVS, Walgreens, Rite Aid, Walmart) carry Shingrix and administer without a physician visit - Ask your primary care physician or internist at your next appointment - Most adults 50+ will have no-cost or low-cost access (see Cost section below)
Cost and Insurance: - Medicare Part D (US): Covered at $0 cost-sharing under the Inflation Reduction Act (effective January 1, 2023) for all ACIP-recommended vaccines including Shingrix - Private insurance (ACA-compliant): Covered at $0 copay in-network for ACIP-recommended vaccines - Without insurance: Full retail cost is approximately $200–265 per dose ($400–530 for the full series) - GoodRx and Cost Plus Drugs may reduce out-of-pocket costs for the uninsured — check availability in your area
Expected Side Effects: Shingrix has a high rate of local and systemic reactions — more than most vaccines — because its adjuvant (AS01B) is designed to provoke a strong immune response. This is expected, not a sign of a problem. - Local (injection site): Arm soreness, redness, swelling — very common - Systemic: Fatigue, muscle aches, headache, shivering, fever, GI upset — common especially after dose 2 - Most reactions resolve within 1–3 days - About 1 in 6 recipients experiences reactions intense enough to interfere briefly with normal activities - Scheduling each dose on a Thursday or Friday allows the weekend for recovery
What It Will Not Do: - Shingrix is not a treatment for active shingles — it must be given when you are not in an active outbreak - It does not eliminate VZV from your body; it trains the immune system to suppress reactivation - The biological aging benefits in the Kim & Crimmins study are associational — an RCT confirming age reversal effects has not been conducted
Priority for Longevity: For any adult 50+ building a longevity protocol, Shingrix should be one of the first interventions addressed. It is low effort (two clinic or pharmacy visits), extremely well-tolerated beyond short-lived side effects, free or near-free for most people, and now linked to measurable multi-system biological age improvement in a large population cohort. The evidence-to-effort ratio is unusually favorable compared to many supplements and interventions that receive far more attention in the longevity community.
Supports
Kim JK, Crimmins EM
Cohort analysis of 3,884 US adults aged 70+ from the Health and Retirement Study. Shingles vaccination was associated with significantly slower biological aging across all five aging measures: epigenetic age (p=0.0001), DunedinPACE (p=0.009), transcriptomic age (p=0.04), proteomic age (p=0.02), and composite biological age score (p=0.009). Effects persisted more than four years post-vaccination.
View paperSupports
Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, et al.
ZOE-70 phase 3 RCT in 13,900 adults aged 70+. Shingrix showed 89.8% efficacy against herpes zoster and 88.8% against postherpetic neuralgia in adults 70+, demonstrating that efficacy is maintained in the oldest age groups where shingles risk is highest.
View paperSupports
Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al.
ZOE-50 phase 3 RCT in 15,411 adults aged 50+. Shingrix demonstrated 97.2% efficacy against herpes zoster in adults 50–69 and 91.3% in those 70+. Confirmed Shingrix as the dominant vaccine replacing Zostavax, with efficacy maintained through 4 years of follow-up.
View paper